Identification of Potential Drug Targets of Broad-Spectrum Inhibitors with a Michael Acceptor Moiety Using Shotgun Proteomics

• Published in: Viruses 2021-09, Vol.13 (9), p.1756
• Main Authors: Chu, Hao-Wei, Sethy, Bidyadhar, Hsieh, Pei-Wen, Horng, Jim-Tong
• Format: Article
• Language: English
• Subjects: Amino acids; Anti-inflammatory agents; Antiviral agents; Antiviral Agents - chemistry; Antiviral Agents - isolation & purification; antiviral drug; Carbonyl compounds; Chemical bonds; Drug development; Drug Discovery - methods; Drug interaction; Drug resistance; HIV; Host Microbial Interactions - drug effects; Human immunodeficiency virus; Humans; Inflammation; Influenza; influenza virus; itaconic acid; mass spectrometry; Michael addition; Nucleophiles; Organic Chemicals - chemistry; Peptides; Pharmaceutical Preparations - chemistry; Proteins; Proteomics; Proteomics - methods; Review; Therapeutic targets; Viral infections; Viruses
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v13091756

The Michael addition reaction is a spontaneous and quick chemical reaction that is widely applied in various fields. This reaction is performed by conjugating an addition of nucleophiles with α, β-unsaturated carbonyl compounds, resulting in the bond formation of C-N, C-S, C-O, and so on. In the development of molecular materials, the Michael addition is not only used to synthesize chemical compounds but is also involved in the mechanism of drug action. Several covalent drugs that bond via Michael addition are regarded as anticarcinogens and anti-inflammatory drugs. Although drug development is mainly focused on pharmaceutical drug discovery, target-based discovery can provide a different perspective for drug usage. However, considerable time and labor are required to define a molecular target through molecular biological experiments. In this review, we systematically examine the chemical structures of current FDA-approved antiviral drugs for potential Michael addition moieties with α, β-unsaturated carbonyl groups, which may exert an unidentified broad-spectrum inhibitory mechanism to target viral or host factors. We thus propose that profiling the targets of antiviral agents, such as Michael addition products, can be achieved by employing a high-throughput LC-MS approach to comprehensively analyze the interaction between drugs and targets, and the subsequent drug responses in the cellular environment to facilitate drug repurposing and/or identify potential adverse effects, with a particular emphasis on the pros and cons of this shotgun proteomic approach.